Prevention and detection of hydroxychloroquine-induced retinopathy in patients with systemic autoimmune diseases

Despite advancements in understanding and detecting HCQ retinopathy, challenges remain in defining a truly safe dose, achieving early detection, and ensuring adherence to screening guidelines. Ongoing research into imaging biomarkers, genetic susceptibility, and AI-driven tools aims to enhance early detection and personalize screening, ultimately improving outcomes and reducing vision loss.